RU2012124817A - Макроциклические лактоновые производные, применяемые для лечения рака - Google Patents
Макроциклические лактоновые производные, применяемые для лечения рака Download PDFInfo
- Publication number
- RU2012124817A RU2012124817A RU2012124817/04A RU2012124817A RU2012124817A RU 2012124817 A RU2012124817 A RU 2012124817A RU 2012124817/04 A RU2012124817/04 A RU 2012124817/04A RU 2012124817 A RU2012124817 A RU 2012124817A RU 2012124817 A RU2012124817 A RU 2012124817A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- hydroxy
- alkyl
- alkoxy
- halogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 17
- 201000011510 cancer Diseases 0.000 title claims 13
- 150000002596 lactones Chemical class 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 81
- 125000000217 alkyl group Chemical group 0.000 claims abstract 72
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 59
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 51
- 239000001257 hydrogen Substances 0.000 claims abstract 51
- 229910052736 halogen Inorganic materials 0.000 claims abstract 48
- 150000002367 halogens Chemical group 0.000 claims abstract 48
- 125000003118 aryl group Chemical group 0.000 claims abstract 39
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 33
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 29
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 11
- -1 -NHCHR Chemical group 0.000 claims abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 10
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims abstract 6
- 150000002431 hydrogen Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 239000012453 solvate Substances 0.000 claims 21
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 16
- 206010038389 Renal cancer Diseases 0.000 claims 16
- 201000010982 kidney cancer Diseases 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 8
- 206010005003 Bladder cancer Diseases 0.000 claims 8
- 206010006143 Brain stem glioma Diseases 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 8
- 206010014733 Endometrial cancer Diseases 0.000 claims 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 8
- 208000017604 Hodgkin disease Diseases 0.000 claims 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 8
- 208000000172 Medulloblastoma Diseases 0.000 claims 8
- 208000034578 Multiple myelomas Diseases 0.000 claims 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 8
- 206010029260 Neuroblastoma Diseases 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 8
- 208000007641 Pinealoma Diseases 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 8
- 206010057644 Testis cancer Diseases 0.000 claims 8
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 8
- 201000010881 cervical cancer Diseases 0.000 claims 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 8
- 201000004101 esophageal cancer Diseases 0.000 claims 8
- 206010017758 gastric cancer Diseases 0.000 claims 8
- 201000010536 head and neck cancer Diseases 0.000 claims 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims 8
- 208000032839 leukemia Diseases 0.000 claims 8
- 201000007270 liver cancer Diseases 0.000 claims 8
- 208000014018 liver neoplasm Diseases 0.000 claims 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 8
- 201000008968 osteosarcoma Diseases 0.000 claims 8
- 201000002528 pancreatic cancer Diseases 0.000 claims 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 8
- 201000011549 stomach cancer Diseases 0.000 claims 8
- 201000003120 testicular cancer Diseases 0.000 claims 8
- 201000002510 thyroid cancer Diseases 0.000 claims 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010060971 Astrocytoma malignant Diseases 0.000 claims 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 201000000582 Retinoblastoma Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 201000007335 cerebellar astrocytoma Diseases 0.000 claims 4
- 208000030239 cerebral astrocytoma Diseases 0.000 claims 4
- 201000003115 germ cell cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000030883 malignant astrocytoma Diseases 0.000 claims 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002267 hypothalamic effect Effects 0.000 claims 2
- 210000003016 hypothalamus Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 208000022982 optic pathway glioma Diseases 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 0 CCC(C1C)ON=C1C=C[C@](C)C(*)C=CC Chemical compound CCC(C1C)ON=C1C=C[C@](C)C(*)C=CC 0.000 description 2
- DGRLAPOMRSTBKD-RIDBUNHASA-N CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OC)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O Chemical compound CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OC)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O DGRLAPOMRSTBKD-RIDBUNHASA-N 0.000 description 1
- UTFKCUQIZRAOLX-YDAYUJLSSA-N CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OCC(N1CCN(C)CC1)=O)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O Chemical compound CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OCC(N1CCN(C)CC1)=O)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O UTFKCUQIZRAOLX-YDAYUJLSSA-N 0.000 description 1
- ZTJUYRRLFGFSBD-CVSBPSRCSA-N CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OCC(O)=O)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O Chemical compound CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OCC(O)=O)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O ZTJUYRRLFGFSBD-CVSBPSRCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26185609P | 2009-11-17 | 2009-11-17 | |
| US61/261,856 | 2009-11-17 | ||
| PCT/IB2010/055161 WO2011061666A1 (en) | 2009-11-17 | 2010-11-15 | Macrocyclic lactone derivatives for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012124817A true RU2012124817A (ru) | 2013-12-27 |
Family
ID=43566625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012124817/04A RU2012124817A (ru) | 2009-11-17 | 2010-11-15 | Макроциклические лактоновые производные, применяемые для лечения рака |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8637683B2 (enExample) |
| EP (1) | EP2501689A1 (enExample) |
| JP (1) | JP2013510899A (enExample) |
| KR (1) | KR20120092677A (enExample) |
| CN (1) | CN102666523A (enExample) |
| AU (1) | AU2010320557A1 (enExample) |
| CA (1) | CA2792198A1 (enExample) |
| IL (1) | IL219807A0 (enExample) |
| MX (1) | MX2012005618A (enExample) |
| NZ (1) | NZ600660A (enExample) |
| RU (1) | RU2012124817A (enExample) |
| WO (1) | WO2011061666A1 (enExample) |
| ZA (1) | ZA201204488B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600662A (en) * | 2009-11-17 | 2014-05-30 | Piramal Entpr Ltd | Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
| WO2014118740A1 (en) * | 2013-02-04 | 2014-08-07 | Piramal Enterprises Limited | Macrocyclic lactone derivatives and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9504617D0 (sv) * | 1995-12-22 | 1995-12-22 | Astra Ab | Active compounds II |
| NZ600662A (en) * | 2009-11-17 | 2014-05-30 | Piramal Entpr Ltd | Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
-
2010
- 2010-11-15 CA CA2792198A patent/CA2792198A1/en not_active Abandoned
- 2010-11-15 CN CN201080057594XA patent/CN102666523A/zh active Pending
- 2010-11-15 EP EP10798188A patent/EP2501689A1/en not_active Withdrawn
- 2010-11-15 JP JP2012539450A patent/JP2013510899A/ja active Pending
- 2010-11-15 AU AU2010320557A patent/AU2010320557A1/en not_active Abandoned
- 2010-11-15 RU RU2012124817/04A patent/RU2012124817A/ru not_active Application Discontinuation
- 2010-11-15 KR KR1020127015787A patent/KR20120092677A/ko not_active Withdrawn
- 2010-11-15 MX MX2012005618A patent/MX2012005618A/es not_active Application Discontinuation
- 2010-11-15 NZ NZ600660A patent/NZ600660A/en not_active IP Right Cessation
- 2010-11-15 WO PCT/IB2010/055161 patent/WO2011061666A1/en not_active Ceased
- 2010-11-15 US US13/510,458 patent/US8637683B2/en not_active Expired - Fee Related
-
2012
- 2012-05-15 IL IL219807A patent/IL219807A0/en unknown
- 2012-06-18 ZA ZA2012/04488A patent/ZA201204488B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102666523A (zh) | 2012-09-12 |
| IL219807A0 (en) | 2012-07-31 |
| WO2011061666A1 (en) | 2011-05-26 |
| ZA201204488B (en) | 2014-08-27 |
| US20120245183A1 (en) | 2012-09-27 |
| JP2013510899A (ja) | 2013-03-28 |
| NZ600660A (en) | 2014-02-28 |
| MX2012005618A (es) | 2012-08-15 |
| US8637683B2 (en) | 2014-01-28 |
| KR20120092677A (ko) | 2012-08-21 |
| CA2792198A1 (en) | 2011-05-26 |
| EP2501689A1 (en) | 2012-09-26 |
| AU2010320557A1 (en) | 2012-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6527534B2 (ja) | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| RU2012119488A (ru) | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором | |
| IL268030B2 (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| HK1246645A1 (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
| HK1245260A1 (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| NZ712378A (en) | Synthetic methods for spiro-oxindole compounds | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| CA3002884A1 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
| RU2016141052A (ru) | Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака | |
| HK1254469A1 (zh) | 稠合双环嘧啶衍生物及其用途 | |
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| TW201811793A (zh) | 吡咯並苯並二氮呯類和彼等之共軛物類 | |
| NZ598521A (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
| ES2714100T3 (es) | Compuestos de quinolina fusionados como inhibidores de mTor, pi3k | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| ES3037417T3 (en) | Purine derivatives as sik-3 inhibitors | |
| CN114222740A (zh) | 新型极光激酶抑制剂及其用途 | |
| JP2013511526A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150128 |